Metoject 7.5 mg

Metoject 7.5 mg is a medicine authorised by Swissmedic under authorisation number 57272. The authorisation holder is Gebro Pharma AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 02 September 2005 and the authorisation is valid without a time limit. ATC code L04AX03 places the medicine in the group Immunosuppressants.

Dispensing category A
Authorisation number 57272
ATC L04AX03
Synthetic medicines

Authorisation data
Authorisation number	57272
Name	Metoject 7.5 mg
Full name	Metoject 7.5 mg, Injektionslösung
Authorisation holder	Gebro Pharma AG
Medicinal product code	Synthetic medicines
Dispensing category	A · Prescription, not repeatable
ATC code	L04AX03
First authorisation	02 September 2005
Authorisation validity	unlimited

Strengths
No.	Name	Dispensing category	Authorisation date
6	Metoject 7.5 mg, Injektionslösung	A	27 November 2008
7	Metoject 10 mg, Injektionslösung	A	27 November 2008
8	Metoject 15 mg, Injektionslösung	A	27 November 2008
9	Metoject 20 mg, Injektionslösung	A	27 November 2008
10	Metoject 25 mg, Injektionslösung	A	27 November 2008
11	Metoject 30 mg, Injektionslösung	A	02 March 2011
12	Metoject 12.5 mg, Injektionslösung	A	17 November 2011
13	Metoject 17.5 mg, Injektionslösung	A	17 November 2011
14	Metoject 22.5 mg, Injektionslösung	A	17 November 2011
15	Metoject 27.5 mg, Injektionslösung	A	17 November 2011

Scroll the table sideways

Pack sizes
Pack code	Quantity	Unit	ATC	IT code	Dispensing category
2	1	Spritze(n)	L04AX03	07.10.6.	A
40	1	Spritze(n)	L04AX03	07.10.6.	A
60	4	Spritze(n)	L04AX03	07.10.6.	A
61	6	Spritze(n)	L04AX03	07.10.6.	A
62	12	Spritze(n)	L04AX03	07.10.6.	A
63	24	Spritze(n)	L04AX03	07.10.6.	A
4	1	Spritze(n)	L04AX03	07.10.6.	A
44	1	Spritze(n)	L04AX03	07.10.6.	A
64	4	Spritze(n)	L04AX03	07.10.6.	A
65	6	Spritze(n)	L04AX03	07.10.6.	A
66	12	Spritze(n)	L04AX03	07.10.6.	A
67	24	Spritze(n)	L04AX03	07.10.6.	A
6	1	Spritze(n)	L04AX03	07.10.6.	A
48	1	Spritze(n)	L04AX03	07.10.6.	A
68	4	Spritze(n)	L04AX03	07.10.6.	A
69	6	Spritze(n)	L04AX03	07.10.6.	A
70	12	Spritze(n)	L04AX03	07.10.6.	A
71	24	Spritze(n)	L04AX03	07.10.6.	A
8	1	Spritze(n)	L04AX03	07.10.6.	A
52	1	Spritze(n)	L04AX03	07.10.6.	A
72	4	Spritze(n)	L04AX03	07.10.6.	A
73	6	Spritze(n)	L04AX03	07.10.6.	A
74	12	Spritze(n)	L04AX03	07.10.6.	A
75	24	Spritze(n)	L04AX03	07.10.6.	A
10	1	Spritze(n)	L04AX03	07.10.6.	A
56	1	Spritze(n)	L04AX03	07.10.6.	A
76	4	Spritze(n)	L04AX03	07.10.6.	A
77	6	Spritze(n)	L04AX03	07.10.6.	A
78	12	Spritze(n)	L04AX03	07.10.6.	A
79	24	Spritze(n)	L04AX03	07.10.6.	A
12	1	Spritze(n)	L04AX03	07.10.6.	A
80	1	Spritze(n)	L04AX03	07.10.6.	A
81	4	Spritze(n)	L04AX03	07.10.6.	A
82	6	Spritze(n)	L04AX03	07.10.6.	A
83	12	Spritze(n)	L04AX03	07.10.6.	A
84	24	Spritze(n)	L04AX03	07.10.6.	A
14	1	Spritze(n)	L04AX03	07.10.6.	A
85	1	Spritze(n)	L04AX03	07.10.6.	A
86	4	Spritze(n)	L04AX03	07.10.6.	A
87	6	Spritze(n)	L04AX03	07.10.6.	A
88	12	Spritze(n)	L04AX03	07.10.6.	A
89	24	Spritze(n)	L04AX03	07.10.6.	A
16	1	Spritze(n)	L04AX03	07.10.6.	A
90	1	Spritze(n)	L04AX03	07.10.6.	A
91	4	Spritze(n)	L04AX03	07.10.6.	A
92	6	Spritze(n)	L04AX03	07.10.6.	A
93	12	Spritze(n)	L04AX03	07.10.6.	A
94	24	Spritze(n)	L04AX03	07.10.6.	A
18	1	Spritze(n)	L04AX03	07.10.6.	A
95	1	Spritze(n)	L04AX03	07.10.6.	A
96	4	Spritze(n)	L04AX03	07.10.6.	A
97	6	Spritze(n)	L04AX03	07.10.6.	A
98	12	Spritze(n)	L04AX03	07.10.6.	A
99	24	Spritze(n)	L04AX03	07.10.6.	A
20	1	Spritze(n)	L04AX03	07.10.6.	A
100	1	Spritze(n)	L04AX03	07.10.6.	A
101	4	Spritze(n)	L04AX03	07.10.6.	A
102	6	Spritze(n)	L04AX03	07.10.6.	A
103	12	Spritze(n)	L04AX03	07.10.6.	A
104	24	Spritze(n)	L04AX03	07.10.6.	A

Scroll the table sideways

Medicines in the same ATC group

Jylamvo 2 mg/mlAuthorisation number 68411 · IDEOGEN AG · ATC L04AX03A Methotrexat Accord 7.5 mg/0.15 mlAuthorisation number 66780 · Accord Healthcare AG · ATC L04AX03A Methotrexat Accord 7.5 mg/0.15 mlAuthorisation number 68244 · Accord Healthcare AG · ATC L04AX03A Methotrexat Orion rheuma/derm 2.5 mgAuthorisation number 66019 · Orion Pharma AG · ATC L04AX03A Methotrexat-Mepha rheuma/derm 7.5 mg/0.30 mlAuthorisation number 65510 · Mepha Pharma AG · ATC L04AX03A Methrexx 7.5 mg/0.75 mlAuthorisation number 62083 · Sandoz Pharmaceuticals AG · ATC L04AX03A Metoject Autoinjektor 7.5 mg/0.15 mlAuthorisation number 65672 · Gebro Pharma AG · ATC L04AX03A Nordimet 7.5 mg/0.3 mlAuthorisation number 65839 · Nordic Pharma GmbH · ATC L04AX03A Nordimet 7.5 mg/0.3 mlAuthorisation number 66568 · Nordic Pharma GmbH · ATC L04AX03A

Other medicines from this authorisation holder

Alacare 2 mg/cm2Authorisation number 62687 · ATC L01XD04B Axhidrox 2Authorisation number 69243 · ATC D11AA01B Becetamol CAuthorisation number 55651D Dalingo 82.5 mgAuthorisation number 69956 · ATC N02BF02B Dexibuprofen Fairmed 200 mgAuthorisation number 68144B GeloDuratAuthorisation number 55928 · ATC R05CAD HovaAuthorisation number 51838 · ATC N05CXD Lactoferment 10Authorisation number 51102 · ATC A07FA01D

Frequently asked questions

Is Metoject 7.5 mg authorised in Switzerland?

Yes. Metoject 7.5 mg is authorised by Swissmedic under authorisation number 57272, data as of 01 September 2026. The authorisation is valid without a time limit.

Which dispensing category does Metoject 7.5 mg have?

Metoject 7.5 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Metoject 7.5 mg?

The authorisation holder is Gebro Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.